haematology

---

NIHR Portfolio Studies - open to recruitment:

    

---

RADAR (UK-MRA Myeloma XV)
Principal Investigator: Dr Arun Alfred
Sponsor: University of Leeds
Comparing treatment escalation and de-escalation strategies in newly diagnosed patients with multiple myeloma. 

  

---

STATIC: Intermittent vs Continuous treatment strategies in CLL
Principal Investigator: Dr Kathryn Goddard
Sponsor: University of Leeds
The primary aim of this study is to assess whether patients with Chronic Lymphocytic Leukaemia (CLL) on long-term treatment with BTK inhibitor (including ibrutinib) have similar disease control with an intermittent treatment strategy compared with standard continuous treatment. 

 

---

REPAIR-MDS
Principal Investigator: Dr Arun Alfred
Co-investigators: Dr Kathryn Goddard, Dr James Taylor, Dr Joe Joseph
Sponsor: University of Warwick
This study is to evaluate haematological improvement in patients with low risk Myelodysplastic syndromes (MDS) by comparing VBaP vs danazol in patients who have either received Erythropoiesis Stimulating Agents (ESAs) and list response, no responded to ESAs or are deemed unlikely to respond to ESAs. 

  
    

---

SECURE
Principal Investigator: Dr Arun Alfred
Co-investigators: Dr Kathryn Goddard, Dr James Taylor, Dr Joe Joseph
Sponsor: Oxford University Hospitals NHS Foundation Trust
This study aims to find out more about the role of family history and demographic factors in the development of MGUS (monoclonal gammopathy of undetermined significance). it will also find out more about the psychological impact of an MGUS diagnosis and individual quality of life. 

nihr portfolio studies - in follow-up:

​DLBCL: A trial of ibrutinib with chemotherapy and rituximab for a type of diffuse large B cell lymphoma (PHOENIX)
Principal Investigator: Dr Arun Alfred
Sponsor: Celltrion Inc. 
This trial is looking at a drug called ibrutinib for a type of non Hodgkin lymphoma called diffuse large B cell lymphoma (DLBCL). It is for people who have a particular type of DLBCL and who haven’t had any other treatment for their lymphoma.
​

---

FLAIR: A trial of ibrutinib with rituximab for chronic lymphocytic leukaemia
Principal Investigator: Dr Kathryn Goddard
Sponsor: University of Leeds
This trial is comparing ibrutinib alongside rituximab with fludarabine, cyclophosphamide, rituximab and venetoclax for chronic lymphocytic leukaemia. This trial is for people who haven’t yet had treatment for their chronic lymphocytic leukaemia (CLL).

---

nihr portfolio studies - in set up:

PROPEL
Principal Investigator: Dr James Taylor
Sponsor: University of Warwickshire & University Hospitals Coventry and Warwickshire
This trial aims to establish the clinical impact and cost-effectiveness of best practice usual care compared to a multiphasic multimodal personalised prehabilitation care package on fatigue, emotional wellbeing and quality of life in patients in remission following induction chemotherapy. 

Image credit: "A test tube tray containing a number of purple tipped vacutainer tubes. Original image sourced from US Government department: Public Health Image Library, Centers for Disease Control and Prevention. https://www.rawpixel.com/image/2288494/free-photo-image-laboratory-medical-test